EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

High-dose versus low-dose block-and-replace treatment for a first episode of Graves’ disease

Arnaud Smolders, Aglaia Kyrilli, Stefan Matei Constantinescu iD, Bernard Corvilain, Chantal Daumerie, Maria-Cristina Burlacu iD

European Thyroid Journal · 2025

DOI: 10.1530/etj-25-0039 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Arnaud Smolders und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The optimal treatment with antithyroid drugs (ATDs) for a first episode of Graves’ disease (GD) remains controversial.

Methods

Retrospective, two academic centres study of newly diagnosed GD between 1990 and 2022, treated with ATD in block-and-replace (B+R) regimen for at least 12 months and followed up for at least 1 year after ATD discontinuation or until disease relapse. Sixty patients received high-dose B+R (HD) with fixed ATD dose maintained during the study, and 60 patients received low-dose B+R (LD) with lower ATD dose adjusted during the study.

Results

Baseline characteristics were similar in both groups. The point-prevalence of euthyroidism was not different between HD and LD (38 vs 47%, P = 0.460 at 6 months, 69 vs 82%, P = 0.194 at 12 months, 70 vs 78%, P = 0.370 at 18 months, respectively). At 18 months, 27% HD vs 38% LD (P = 0.242) had thyroid eye disease. There were no differences in the number or type of ATD-related adverse events (AE) (no AE 73 vs 78%, P = 0.707). LD received mean lower ATD dose (15.3 ± 4.2 vs 30.0 ± 0.0 mg/day, P < 0.001) and lower levothyroxine dose (72.6 ± 16.7 vs 100.6 ± 24.5 μg/day, P < 0.001). After a first course of ATD, 63% of HD patients and 60% of LD patients relapsed (P = 0.707) after a median time (interquartile range) of 11.0 (18) vs 7.0 (19) months (P = 0.109).

Conclusion

We observed similar relapse rates in patients with a first episode of GD receiving up to 50% less ATD and 30% less levothyroxine dose than high-dose B+R regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseAntithyroid AgentsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeDose-Response Relationship, DrugRecurrenceThyroxineAged

Stichwörter der Autor:innen

Graves’ diseaseantithyroid drugsblock-and-replacedose

Substanzen

Antithyroid AgentsThyroxine

Autor:innen und Institutionen

ORCID-Profile: Stefan Matei Constantinescu, Maria-Cristina Burlacu

Zitieren

APA

Smolders, A., Kyrilli, A., Constantinescu, S. M., Corvilain, B., Daumerie, C., & Burlacu, M. C. (2025). High-dose versus low-dose block-and-replace treatment for a first episode of Graves’ disease. European Thyroid Journal. https://doi.org/10.1530/etj-25-0039

Vancouver

Smolders A, Kyrilli A, Constantinescu SM, Corvilain B, Daumerie C, Burlacu MC. High-dose versus low-dose block-and-replace treatment for a first episode of Graves’ disease. European Thyroid Journal. 2025. doi:10.1530/etj-25-0039

BibTeX
@article{Smolders2025,
  author = {Smolders, Arnaud and Kyrilli, Aglaia and Constantinescu, Stefan Matei and Corvilain, Bernard and Daumerie, Chantal and Burlacu, Maria-Cristina},
  title = {High-dose versus low-dose block-and-replace treatment for a first episode of Graves’ disease},
  journal = {European Thyroid Journal},
  year = {2025},
  doi = {10.1530/etj-25-0039}
}
Kostenlos starten →